Elanco Animal Health (ELAN) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Elanco Animal Health Reports Third Quarter 2025 Results
November 5, 2025 6:27 AM ESTRaising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target
Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% organic constant currency growth Reported Net Loss of $34 million, Adjusted Net Income of $94 million Adjusted EBITDA of $198 million; Adjusted EBITDA Margin of 17.5%Â Reported EPS of $(0.07), Adjusted EPS of $0.19 Net leverage ratio of 3.7x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,645 million to $4,670 million; expect accelerating organic constant currency revenue growth of 6% to... More